Evoq Technologies Announces Launch of First Smartphone-Based Product for Retinal Health Testing

Evoq Technologies has announced the FDA registration of the first in its family of products based on its proprietary smartphone-based biosensor technology. Dubbed the ‘SmartERG’ platform, it’s built to test the eye’s retinal health in unique ways.

"By flashing a controlled light at the eye, we can evoke an electrical-physiological response from the retina that can tell us a lot about its health. When visual responses are delayed or reduced, they are often signatures of disease that lead to vision loss or blindness," Evoq Technologies stated in a news release. "That’s why our tag line is “Seeing Change in a Flash.” With the ability to collect and analyze data on a smartphone, under the guidance of your healthcare provider, we are putting answers about retinal health in everyone’s hands.

The company's first smartphone product is the biophotometer for dark adaptation impairment testing as a Class I medical device. In 2022, Evoq will conduct clinical evaluations of its ophthalmic biosensor and specialty stimulators for submission as class II medical devices with the FDA.

“Our SmartERG Platform will offer a revolutionary delivery method for ophthalmic patient care; with the force multipliers of simple connection of patient to provider, cloud-based analytical services, and a perfect fit for artificial intelligence,” Daniel Lindgren, President of Evoq Technologies, said in a news release. “We are paving the way for cost-effective screening for retinal diseases, such as age-related macular degeneration (AMD), diabetic retinopathy, and glaucoma, effectively using the same standard-of-care as equivalent legacy diagnostic devices, but at fraction of the cost, delivered worldwide.”

Mr. Lindgren said Evoq Technologies is actively working with interested parties on how this technology can positively impact patient care delivery in the clinic, at the bedside, and at home. Evoq Technologies is seeking licensing and partnership opportunities with medical device, pharmaceutical, and health delivery stakeholders who want to ‘Evoq a Revolution.’